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Background: Reactive oxygen species (ROS) production induced by α,β-dicarbonyl compounds and advanced
glycation end products causes renal dysfunction in patients with type 2 diabetes and metabolic syndrome.
Hydrogen-rich water (HRW) increases the H2 level in blood and tissues, thus reducing oxidative stress in animals as
well as humans. In this study, we investigated the effects of HRW on glucose- and α,β-dicarbonyl compound-induced
ROS generation in vitro and in vivo.
Methods: Kidney homogenates from Wistar rats were incubated in vitro with glucose and α,β-dicarbonyl compounds
containing HRW, following which ROS levels were measured. In vivo animal models of metabolic syndrome,
SHR.Cg-Leprcp/NDmcr rats, were treated with HRW for 16 weeks, following which renal ROS production and plasma
and renal α,β-dicarbonyl compound levels were measured by liquid chromatograph mass spectrometer.
Results: HRW inhibited glucose- and α,β-dicarbonyl compound-induced ROS production in kidney homogenates from
Wistar rats in vitro. Furthermore, SHR.Cg-Leprcp/NDmcr rats treated with HRW showed a 34% decrease in ROS
production. Moreover, their renal glyoxal, methylglyoxal, and 3-deoxyglucosone levels decreased by 81%, 77%, and
60%, respectively. Positive correlations were found between renal ROS levels and renal glyoxal (r= 0.659, p=0.008) and
methylglyoxal (r= 0.782, p=0.001) levels.
Conclusion: These results indicate that HRW inhibits the production of α,β-dicarbonyl compounds and ROS in the
kidneys of SHR.Cg-Leprcp/NDmcr rats. Therefore, it has therapeutic potential for renal dysfunction in patient with type 2
diabetes and metabolic syndrome.
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glycation end productsBackground
Nonenzymatic glycation of proteins and the Maillard re-
action result in the formation of advanced glycation end
products (AGEs), which are associated with the patho-
genesis of type 2 diabetes [1]. During the formation of
AGEs, α,β-dicarbonyl compounds such as glyoxal,
methylglyoxal, and 3-deoxyglucosone are produced as
reactive intermediates [2]. Patients with type 2 diabetes* Correspondence: michio1@med.shimane-u.ac.jp
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reproduction in any medium, provided the orhave increased plasma levels of these compounds [3].
Moreover, AGEs [4, 5], and α,β-dicarbonyl compounds
[6] produce reactive oxygen species (ROS). Oxidative
stress is of particular interest in the pathogenesis of dia-
betic nephropathy [7], the latter being the leading cause
of end-stage renal disease.
Molecular hydrogen (H2), a potent free radical scavenger,
selectively reduces the levels of the hydroxyl radical and
peroxynitrite, which is the most cytotoxic ROS [8]. Con-
sumption of water saturated with H2 [H2-rich water
(HRW)] increases the blood H2 level and reduces renal oxi-
dative stress in mice with cisplatin-induced nephrotoxicityl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chronic allograft nephropathy [11].
We previously demonstrated that HRW confers consid-
erable benefits against renal abnormalities in SHR.Cg-
Leprcp/NDmcr (SHRcp) rats, which are metabolic syn-
drome models, at least by preventing glomerulosclerosis
and ameliorating creatinine clearance [12]. Furthermore, a
sufficient supply of HRW may prevent or delay the devel-
opment and progression of type 2 diabetes [13] and meta-
bolic syndrome [14] by protecting against oxidative stress.
However, the exact mechanisms of the beneficial effects of
HRW on diabetic nephropathy remain unknown.
Given the potent free radical-scavenging activity of H2,
we hypothesized that HRW may attenuate the produc-
tion of α,β-dicarbonyl compounds as well as the produc-
tion of ROS from AGEs and α,β-dicarbonyl compounds.
In this study, we investigated whether HRW could in-
hibit glucose- and α,β-dicarbonyl compound-induced
ROS production in vitro and in vivo.
Methods
Animals
Ten-week-old male Wistar rats (Clea Japan, Inc., Japan)
were used for the in vitro experiments. Five-week-old
male SHRcp rats (Disease Model Cooperative Research
Association, Japan) were randomly divided into 2
groups: the HRW-treated group (n = 12), which received
oral HRW, and the control group (n = 12), which
received distilled water. Both groups were treated for
16 weeks as described previously [12]. All rats were
housed under controlled temperature (23 ± 2°C)- and
humidity (50%± 10%)- with a 12-h light–dark cycle. The
Wistar rats were fed normal rat chow (CE-2, Oriental
Yeast Co., Ltd, Japan) while the SHRcp rats were fed
Quick Fat (Clea Japan, Inc.) with ad libitum access to
sterile-water or HRW (Additional file 1: Table S1).
All rats were anesthetized with intraperitoneal sodium
pentobarbital (65 mg/kg), following which their kidneys
were removed, immediately frozen in liquid nitrogen
and stored at −30°C until further use. The kidneys were
homogenized with phosphate buffer (pH, 7.4) in a Teflon
homogenizer. The homogenates were immediately fro-
zen in liquid nitrogen and stored at −30°C until use. All
animal experiments were conducted in accordance with
the procedures outlined in the Guidelines for Animal
Experimentation of Shimane University, compiled from
the Guidelines for Animal Experimentation of the Japa-
nese Association for Laboratory Animal Science.
Generation of HRW
Nakao et al. have described the production and charac-
terization of HRW [14]. HRW was prepared by dipping a
plastic-shelled product (stick) comprising metallic magne-
sium (99.9% pure) and natural stones (Doctor SUISOSUIW;Friendear Inc., Japan) into distilled water. HRW was
freshly prepared every other day in a 200-mL bottle con-
taining the stick, and the H2 concentration was maintained
between 0.3 and 0.4 ppm during the experiment.
In vitro experimentation
Fenton reaction
Kidney homogenates were incubated with or without
HRW in PBS containing 2 mM FeSO4 and 5 mM H2O2
for 60 min at 37°C. After the reaction, one aliquot was
used for lipid peroxide (LPO) measurement and a sec-
ond aliquot was added to ice-cold PBS for ROS
measurement.
Treatment with glucose and α,β-dicarbonyl compounds
Kidney homogenates were incubated with or without
HRW in PBS containing glucose (1, 10, or 100 mM;
Wako Pure Chemical Industries, Japan), glyoxal (2, 20,
or 200 μM; Nacalai Tesque, Inc., Japan), methyglyoxal
(2, 20, or 200 μM; Sigma-Aldrich, USA), or
3-deoxyglucosone (2, 20, or 200 μM, Wako Pure Chem-
ical Industries) for 60 min at 37°C. Ice-cold PBS was
then added and ROS levels were measured.
LPO measurement
LPO concentrations were measured using the thiobarbitu-
ric acid reactive substance assay as described previously
[15], and they were expressed as moles of malondialde-
hyde. Malondialdehyde levels were calculated relative to a
standard preparation of 1,1,3,3-tetraethoxypropane.
ROS measurement
ROS levels were measured as previously described [16]. In
brief, kidney samples were centrifuged at 12,500 g for
10 min at 4°C. The pellets were resuspended in PBS and
sonicated for 3 min in ice-cold water. The substrate 2′,7′-
dichlorofluorescin diacetate (Sigma-Aldrich) was mixed
with the resultant samples, and fluorescence was moni-
tored every 10 min for 60 min in the dark at 37°C. Fluor-
escence was measured with a DTX 880 multimode
detector (Beckman Coulter, Inc., USA) using excitation
and emission filters at 488 and 543 nm, respectively. 2′,7′-
Dichlorofluorescein (Sigma-Aldrich) was used as the
standard. Data were expressed as dichlorofluorescein pro-
duction per minute per milligram of protein. Protein con-
centration was determined by using the Lowry method.
Measurement of α,β-dicarbonyl compounds
The levels of α,β-dicarbonyl compounds in the kidneys and
plasma of the SHRcp rats were measured as described with
a slight modification [3]. In brief, glyoxal, methylglyoxal,
and 3-deoxyglucosone solutions in 10 mM phosphate buf-
fer (pH, 7.4) with 0.005% 3,4-hexanedione (Tokyo Kasei
Organic Chemicals, Japan) as internal standard were
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(Tokyo Kasei Organic Chemicals) at 4°C. The reaction
mixtures were extracted with ethyl acetate, and the organic
layers were dried under nitrogen gas. The dried extracts
were reconstituted with methanol and injected into an li-
quid chromatograph mass spectrometer (LC-MS/MS) sys-
tem. HPLC was combined with ESI-MS in a TSQ
Quantum mass spectrometer (Thermo Fisher Scientific K.
K., Japan). HPLC was conducted in a Luna 5u C18(2)
100 Å LC column (150×2.0 mm, Phenomenex, USA) at
30°C. Samples were eluted with a mobile phase composed
of acetonitrile methanol (4:1, v/v) and water acetic acid
(100:0.1, v/v) in a 10:90 ratio for 5 min, ramped up to a
100:0 ratio after 25 min, and held for 10 min at a flow rate
of 0.1 mL/min. MS/MS was conducted in positive ion
mode, and 2,3-diaminonaphthalene derivatives of methyl-
glyoxal (m/z 195> 127), glyoxal (m/z 181> 127),
3-deoxyglucosone (m/z 285> 221), and 3,4-hexanedione
(m/z 237> 169) were detected and quantified by selected
reaction monitoring.
Statistical analysis
Results are expressed as means ± SEM. Data were ana-
lyzed by Dunnett’s multiple comparison test and Stu-
dent’s t-test. Differences between groups were
considered significant at p-values less than 0.05. All stat-
istical analyses were performed with PASW Statistics
18.0 (IBM-SPSS, Inc., USA).
Results
Fenton reaction-induced ROS and LPO production
ROS and LPO levels by 82% and 62%, respectively, in
the kidney homogenates incubated with H2O2 and





























Figure 1 Effects of HRW on Fenton reaction-induced ROS production.
or without (white bars) 2 mM FeSO4 and 5 mM H2O2 or HRW with 2 mM F
levels were measured. Values represent means ± SEM (n = 3–6/group) *,#p<treatment with HRW (Figure 1). These results are con-
sistent with those of a previous study in which H2 select-
ively reduced the levels of the hydroxyl radical [8]
generated by the Fenton reaction.
Glucose- and α,β-dicarbonyl compound-induced ROS
production
ROS levels were significantly increased after incubation
with glucose or α,β-dicarbonyl compounds; however,
their production was inhibited by treatment with HRW
(Figure 2). These results indicate that HRW inhibited
ROS production induced by glucose and α,β-dicarbonyl
compounds.
Renal ROS levels
As a result of the in vitro findings (Figures 1 and 2),
renal ROS levels were measured in the SHRcp rats after
treatment with HRW for 16 weeks. The renal ROS levels
were significantly decreased by 34% in these treated ani-
mals compared with the controls (Figure 3), indicating
that HRW inhibited ROS production in vivo.
Plasma and renal α,β-dicarbonyl compound levels
Glyoxal and methylglyoxal levels, but not 3-
deoxyglucosone levels, were significantly decreased in
the plasma of HRW-treated SHRcp rats compared with
their control counterparts (Figure 4a–c). Furthermore,
the renal levels of glyoxal, methylglyoxal, and
3-deoxyglucosone decreased by 81%, 77% and 60%, re-
spectively, in the HRW-treated group (Figure 4d–f ).
Positive correlations were found between renal ROS
levels and renal glyoxal (r= 0.659, p= 0.008) and methyl-
glyoxal (r= 0.782, p= 0.001) levels; however, 3-
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Figure 2 Effects of HRW on glucose- and α,β-dicarbonyl compound-induced ROS production. Kidney homogenates from Wistar rats were
incubated with (a) glucose (1, 10, or 100 mM), (b) glyoxal (2, 20, or 200 μM), (c) methylglyoxal (2, 20, or 200 μM), or (d) 3-deoxyglucosone (2, 20,
or 200 μM). Then, ROS levels were measured. Values represent means ± SEM (n = 3–6/group), *p< 0.05 versus controls.
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the production of α,β-dicarbonyl compounds and ROS
in the kidneys of the SHRcp rats.
Discussion
The present study revealed that HRW prevented
glucose- and α,β-dicarbonyl compound-induced ROS
production in vitro (Figure 2) and in vivo (Figure 3). In
the in vivo study, HRW decreased the levels of α,β-dicar-
bonyl compounds in the plasma and kidney (Figure 4).
α,β-Dicarbonyl compounds reportedly form from deg-
radation of glucose in 200 mM PBS (pH, 7.4) [17]. These
compounds can produce free radicals [7, 18] such as the
hydroxyl radical [19], peroxynitrate [20], and the acetyl
radical [21]. H2 selectively decreases the levels of the hy-
droxyl radical and peroxynitrite [8]. Data from the
present study showed that HRW inhibited ROS produc-
tion induced by the Fenton reaction and α,β-dicarbonyl
compounds. Taken together, these results suggest that
HRW decreases hydroxyl radical and peroxynitrate pro-
duction induced by α,β-dicarbonyl compounds.
α,β-Dicarbonyl compound- and glucose-induced oxi-
dative stress is considered to be a cause of renal dysfunc-
tion in vivo. Methylglyoxal and glucose induce renaloxidative damage and podocyte apoptosis in Zucker dia-
betic fatty rats [22] and db/dB mice [23]. Patients with
type 2 diabetes have increased plasma levels of these
compounds [3]. In the present study, we investigated
whether HRW could inhibit α,β-dicarbonyl compound-
induced oxidative stress in vivo. SHRcp rats were chosen
for the present study because they exhibit several meta-
bolic disorders, such as hypertension, hyperglycemia,
hyperinsulinemia, and hyperlipidemia [24]. Histologi-
cally, islet area expansion, fatty liver, and glomerulosis
can be observed in these rats. Therefore, they are con-
sidered to be a suitable animal model for renal dysfunc-
tion with the metabolic syndrome. Renal ROS levels
were significantly decreased in the HRW-treated SHRcp
rats compared with the control group (Figure 3). Fur-
thermore, glyoxal and methylglyoxal levels in plasma
and glyoxal, methylglyoxal, and 3-deoxyglucosone levels
in the kidney were significantly decreased in HRW-
treated animals compared with the control group (Fig-
ure 4). These results indicate that HRW inhibits ROS
production by inhibiting α,β-dicarbonyl compound
production.
Renoprotection does not necessarily depend on blood

























Figure 3 Effect of HRW on renal ROS production in
SHR.Cg-Leprcp/NDmcr rats. Values represent means ± SEM
(n = 12/group), *p< 0.05 versus controls.
Katakura et al. Medical Gas Research 2012, 2:18 Page 5 of 7
http://www.medicalgasresearch.com/content/2/1/18[26] and treatment with angiotensin II receptor blocker
[27], pioglitazone [28], or cobalt [29] protect against























































Figure 4 Effects of HRW on plasma (a–c) and renal (d–f) glyoxal (a, d)
Cg-Leprcp/NDmcr rats. Values represent means ± SEM (n = 12/group), *p<control in SHRcp rats. These reports indicate that reno-
protection is associated with decreased AGE formation
and oxidative stress, thus suggesting that they are poten-
tial therapeutic strategies for renal dysfunction in
patients with type 2 diabetes and metabolic syndrome.
We previously reported that HRW does not affect blood
pressure or blood glucose levels but prevents glomerulo-
sclerosis in SHRcp rats [12]. In the present study, we
noted that HRW inhibited the production of α,β-dicar-
bonyl compounds and ROS in these rats, suggesting that
HRW has a potential therapeutic application for patient
with renal dysfunction.
There are other possible molecular mechanisms to
prevent oxidative stress cause by HRW. Kawamura et al.
[30] have reported that in lung allograft in rats, H2
induces heme oxygenase-1 expression, decreases proin-
flammatory cytokines and the proapoptotic protein Bax,
and increases expression of antiapoptotic protein Bcl-2.
H2 reduces the binding of several transcription factors
such as AP1 and NFκB to the iNOS promoter via inhib-
ition of signal transduction in macrophages [31]. These
reports suggest that the molecular target for HRW not
only inhibits ROS generation but also induces gene ex-
pression of antioxidative enzymes at the transcriptional
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, methylglyoxal (b, e), and 3-deoxyglucosone (c, f) levels in SHR.
0.05 versus controls.
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8 weeks increases superoxide dismutase levels by 39%
and decreases thiobarbituric acid reactive substance
levels by 43% in the urine of subjects with potential
metabolic syndrome [14]. Consumption of HRW is also
associated with a significant decrease in the urinary
levels of 8-isoprostanes, which are endogenous lipid per-
oxidation products [13]. These results indicate that
HRW may have antioxidant activity in humans. Further
studies are necessary to confirm the effects of HRW on
renal dysfunction associated with type 2 diabetes and
metabolic syndrome in humans.
Aminoguanidine, a prototype AGE formation inhibitor,
acts by scavenging α,β-dicarbonyl compounds. Amino-
guanidine has been shown to inhibit the formation of
AGEs and slow the progression of diabetic nephropathy
in animal models [32, 33]. It also significantly decreases
proteinuria in treated subjects [34]. However, aminogua-
nidine is a nonspecific AGE inhibitor that also inhibits
nitric oxide synthase [35] and causes DNA damage [36].
Aminoguanidine cannot be used for the treatment of
diabetic nephropathy because of safety concerns, and
additional clinical studies are required to address the
safety and efficacy of other types of AGE inhibitors [37].
On the other hand, consumption of HRW had no ad-
verse effects on hematological parameters and biometric
parameters during an 8-week study period in humans
[14], suggesting that HRW is safe.
Conclusions
In conclusion, HRW inhibits renal ROS production
induced by glucose and α,β-dicarbonyl compounds
in vitro and renal ROS and α,β-dicarbonyl compound
production in vivo. Therefore, it has therapeutic poten-
tial for the treatment of renal dysfunction in patients
with type 2 diabetes and potential metabolic syndrome.
Additional file
Additional file 1: Table S1. Composition of the MF diet and Quick Fat
diet
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